BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mucosis B.V. And PATH Start Development Of Pneumococcal Vaccines


1/28/2009 1:34:26 PM

Dutch biotechnology company Mucosis B.V. and the global nonprofit organization PATH today announced a partnership to advance the development of pneumococcal vaccine candidates. Under the collaboration agreement, Mucosis will develop intranasal vaccines based on Mucosis’s proprietary pneumococcus-specific antigens and its Mimopath™ technology. PATH will provide approximately €400,000 for a 12-month study to further Mucosis’s preclinical research of multivalent protein vaccine candidates through evaluation of the immunization route and optimization of antigens for protection. Radboud University Nijmegen Medical Centre (The Netherlands) will evaluate vaccine candidates in established models of pneumococcal diseases. If the study results are positive, Mucosis and PATH intend to extend their collaboration.

“Working with PATH offers us yet another opportunity to demonstrate the capabilities of our technology in an important indication” said Govert Schouten, CEO of Mucosis. “Our common goal is to produce a broadly protective pneumococcal vaccine that offers the public health systems efficacy and ease of administration.”

Pneumonia is the leading cause of death in young children in the developing world. Each year, more than two million children die from this disease. Pneumococcus (scientific name Streptococcus pneumoniae), the bacterium that is the most common cause of severe pneumonia, also causes sepsis (blood infection) and meningitis (brain infection), which disable and kill children worldwide. In addition, it is one of the leading causes of otitis media (middle ear infection).

“While current pneumococcal vaccines are effective in preventing morbidity and mortality due to pneumococcal disease, additional vaccines are ultimately needed to expand protection for children in low-income countries, where most pneumococcus deaths occur,” noted Dr. Mark Alderson, director of PATH’s Pneumococcal Vaccine Project. “We are pleased to partner with Mucosis on this approach to developing pneumococcal vaccines that will be effective and affordable in the countries that most urgently need them.”

About Mucosis

Mucosis B.V. is a Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is FluGEM™, an intranasal vaccine to prevent influenza. Mucosis’s vaccines are based on the patented Mimopath™ technology. This technology enables a more natural immune response as well as a broad base of protection.

About Mimopath™ technology

Mimopath™ technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed an easy technique to formulate the L. lactis bacteria into non-living particles that can be loaded with antigens from viral, bacterial, or parasitic origin. The antigen-covered particles form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.

About PATH

PATH is an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. By collaborating with diverse public- and private-sector partners, PATH helps provide appropriate health technologies and vital strategies that change the way people think and act. PATH’s work improves global health and well-being. For more information, please visit www.path.org.



Read at BioSpace.com

PATH
Mucosis B.V.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES